Efficacy of SCH 420814 [preladenant] to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia.

Trial Profile

Efficacy of SCH 420814 [preladenant] to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs Preladenant (Primary) ; Cholinergic receptor antagonists; Propranolol
  • Indications Drug-induced akathisia
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 21 Apr 2017 Status changed from completed to discontinued.
    • 28 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top